Farnesyltransferase inhibitor
Farnesyltransferase inhibitors (FTIs) are a class of experimental cancer drugs that target protein farnesyltransferase with the intention of preventing its action. Farnesyltransferase is an enzyme that plays a key role in cell signaling, and its dysregulation has been implicated in the development of several types of cancer.
Mechanism of Action[edit | edit source]
Farnesyltransferase inhibitors work by blocking the action of the enzyme protein farnesyltransferase. This enzyme is responsible for the post-translational modification of a variety of proteins through a process known as prenylation. Prenylation involves the addition of a farnesyl group to the protein, which allows it to anchor to cell membranes and participate in cell signaling processes.
In many cancers, certain proteins are overactive or present in excessive amounts, leading to uncontrolled cell growth and division. By inhibiting farnesyltransferase, these drugs aim to prevent the prenylation and subsequent activation of these proteins, thereby halting the growth of cancer cells.
Clinical Use[edit | edit source]
Farnesyltransferase inhibitors are currently in the experimental stages of development and have not yet been approved for use in humans. However, they have shown promise in preclinical trials for the treatment of a variety of cancers, including lung cancer, breast cancer, and pancreatic cancer.
Potential Side Effects[edit | edit source]
As with all drugs, farnesyltransferase inhibitors have the potential to cause side effects. These may include nausea, vomiting, diarrhea, and fatigue. More serious side effects may include liver damage and blood clotting disorders.
Future Directions[edit | edit source]
Research is ongoing to further understand the role of farnesyltransferase in cancer and to develop more effective and selective inhibitors of this enzyme. It is hoped that these drugs may eventually provide a new approach to cancer treatment, particularly for cancers that are currently resistant to other forms of therapy.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
